Drug Profile
CTX 471
Alternative Names: CTX-471Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Adimab
- Developer Compass Therapeutics; Merck & Co
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 09 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumors released by Compass Therapeutics
- 10 May 2023 Compass Therapeutics has patents pending for CD137 agonist antibody therapeutic platform and CTX 471 in USA and foreign jurisdictions
- 01 Dec 2022 Phase-I clinical trials in Head and neck cancer (Second-line therapy or greater, Late-stage disease, Combination therapy, Metastatic disease) in USA (IV)